최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
DataON 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Edison 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Kafe 바로가기주관연구기관 | 서울대학교 Seoul National University |
---|---|
연구책임자 | 강건욱 |
보고서유형 | 최종보고서 |
발행국가 | 대한민국 |
언어 | 한국어 |
발행년월 | 2017-02 |
과제시작연도 | 2016 |
주관부처 | 미래창조과학부 Ministry of Science, ICT and Future Planning |
등록번호 | TRKO201800004089 |
과제고유번호 | 1711035885 |
사업명 | 방사선기술개발사업 |
DB 구축일자 | 2018-04-28 |
키워드 | 테라그노시스.표적치료.분자영상.나노의학.생체영상.theragnosis.targeted therapy.molecular imaging.nanomedicine.in vivo imaging. |
○ 테라그노시스 의약품 개발 기초기술 확립
- 생분해입자에 방사성동위원소 표지 최적화함
- RGD 등 신생혈관추적 바이오마커 방사선표지 기술 개발함
- 골드나노입자 표면 개질 및 골드/철/고분자나노입자 방사성동위원소 표지 기술 개발함
- 줄기/면역세포에 방사성동위원소 표적 리포터유전자 이입기술 개발함
○ 테라그노시스 의약품 합성기술 최적화
- 방사선 생분해입자의 생체영상 최적화 및 치료효과 평가함
- 테라그노시스용 방사선표지 RGD 생체영상 및 치료효과 평가함
- 방사성동위원소 및
○ 테라그노시스 의약품 개발 기초기술 확립
- 생분해입자에 방사성동위원소 표지 최적화함
- RGD 등 신생혈관추적 바이오마커 방사선표지 기술 개발함
- 골드나노입자 표면 개질 및 골드/철/고분자나노입자 방사성동위원소 표지 기술 개발함
- 줄기/면역세포에 방사성동위원소 표적 리포터유전자 이입기술 개발함
○ 테라그노시스 의약품 합성기술 최적화
- 방사선 생분해입자의 생체영상 최적화 및 치료효과 평가함
- 테라그노시스용 방사선표지 RGD 생체영상 및 치료효과 평가함
- 방사성동위원소 및 리간드 표지 골드/철/고분자나노입자 영상 평가함
- 치료용 줄기/면역세포에 생체 분자영상 추적기술 최적화함
○ 테라그노시스 의약품 치료/영상 평가 및 임상 적용 후보 도출
- 종양 이중타겟 방사성생분해 입자 임상 후보물질 도출함
- 방사선 나노 테라그노스틱 다중영상 시스템 개발함
- 방사성표지 치료줄기/면역세포 영상추적 융합응용 임상적용 기술 도출함
- 후보물질 최적화 및 비임상 시험함
( 출처 : 보고서 요약서 3p )
Purpose&Contents
To develop personalized medicine which decreases side effects and enhances treatment effects in incurable disease, radiolabeled nano drug transmitters or cell therapeutic medicines makes imaging or radiotherapy possible simultaneously. This leads to the development and analysis o
Purpose&Contents
To develop personalized medicine which decreases side effects and enhances treatment effects in incurable disease, radiolabeled nano drug transmitters or cell therapeutic medicines makes imaging or radiotherapy possible simultaneously. This leads to the development and analysis of technology and medicine which make the treatment and biomonitoring possible simultaneously based on radio-theragnosis generic technology development.
Results
1. Radio-theragnosis generic technology development
○ Development of ligand labeling technology such as antibodies, peptides and aptamer on biodegradable particle
- Optimization of ligand and radioisotope labeling technology
- Confirm the tumor target imaging using ligand-biodegradable complex
○ In vitro evaluation of radio-labeling RGD conjugated nanoparticles uptake
- Development of three nanoparticle conjugates with RGD peptide ligands - Confirm the cell targeting concentration (IC50 < 5nM)
- In vitro stability test (>90%)
○ Development of ligand labeling technology using candidate nano-particle substances such as gold, oxidized iron, and polymers
- Confirm the targeted/non-targeted cell uptake ratio (>200%)
- Confirm imaging of cadidate nano-particle substances in vivo
○ Optimization of radio-isotope uptake in reporter gene trasfected stem/immune cells
- Confirm differentiation capacity of reporter gene introduced therapeutic stem cell
- Confirm the distribution of therapeutic stem cell in normal mouse
2. Optimization of radio-theragnosis generic technology development
○ Optimization of radio-labeling biodegradable particle for imaging and therapy of cancer
- Evaluation of in vitro uptake and in vivo imaging
- Mornitoring of therapeutic effect using theragnostic albumin
○ Optimization of radiolabeled nano theragnostic materials
- Development of therapeutic agent loaded liposome nanoparticle and chitosan hydrogel nanoparticle
- Therapeutic agent loaded double layered gold nanoparticle and HIFU treatment
- Development and evaluation of F-18 labeled RGD-SPION-drug
○ Optimization of cell tracking system using radiolabeled therapeutic stem / immune cells in in vivo model
- Establishment of cell labeling technique with the nuclear medicine probe
- Assessment of stability and safety of the nuclear medicine probe in in vitro
- Separation of microvesicles from tumor/immune cells and characterization of the microvesicles
3. Leading of clinical candidates in radio-theragnosis generic technology development
○ Leading of clinical candidates in radio-labeling biodegradable particle
- Optimization of targeted imaging and therapeutic effect using theragnostic albumin
- Evaluation of biodistribution using theragnostic albumin
○ Development of multi-modal imaging system using radiolabeled nanoparticles
- Evaluation of therapeutic agent loaded liposome nanoparticle and chitosan hydrogel nanoparticle
- Evaluation of correlation with imaging of F-18 labeled RGD-SPION-drug and angiogenesis
- Evaluation of therapeutic agent loaded double layered gold nanoparticle and HIFU treatment
○ Clinical applicable technology of radiolabeled therapeutic stem / immune cells
- Nuclear imaging of cell using nuclear medicine probe and combination with other imagings
- Optimization of nuclear molecular imaging and its applications
- Potentiation of therapetuic effect of cell therapy using microvesicle preapplication
○ Optimization of candidate material and GLP(good laboratory practice) test
- Optimization of conjugated number of ligands and linker on albumin surface
- Safety evaluation and toxicity test of nano probes
Expected Contribution
○ Radio-theragnosis medicine and technology development based on deduction of several nano-particle candidates, establishment of manufacturing technique and establishment of radio-labeling technology maximize the effect of research.
○ Theragnosis is a important technology for personalized therapy to monitoring drug and therapeutic materials, which makes imaging or radiotherapy possible simultaneously.
○ Theragnostic agents and theragnosis generic technology development will be helpful to reduction of psychological and economical difficulties and improvement of life quality of cancer patients.
( 출처 : SUMMARY 6p )
과제명(ProjectTitle) : | - |
---|---|
연구책임자(Manager) : | - |
과제기간(DetailSeriesProject) : | - |
총연구비 (DetailSeriesProject) : | - |
키워드(keyword) : | - |
과제수행기간(LeadAgency) : | - |
연구목표(Goal) : | - |
연구내용(Abstract) : | - |
기대효과(Effect) : | - |
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.